WLLW.CN - Willow Biosciences Inc.

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
1.3200
-0.0300 (-2.22%)
At close: 3:10PM EDT
Stock chart is not supported by your current browser
Previous Close1.3500
Open1.3500
Bid1.3000 x N/A
Ask1.3200 x N/A
Day's Range1.3000 - 1.3500
52 Week Range1.0000 - 5.2500
Volume4,775
Avg. Volume41,824
Market Cap103.338M
Beta (3Y Monthly)2.52
PE Ratio (TTM)N/A
EPS (TTM)-0.7610
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile7 days ago

    Betting Big on the New Age of Synthetic Cannabinoids - CFN Media

    Seattle, Washington--(Newsfile Corp. - June 18, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering Willow Biosciences (CSE: WLLW) and its next-generation cannabis manufacturing process.In the U.S. and globally, there is an explosion in demand for cannabinoids, naturally occurring components of the cannabis plant, for medical research purposes. The overarching problem, however, is that the ...

  • Newsfile20 days ago

    InvestmentPitch Media Video Discusses Willow Biosciences' Joint Development Agreement with Noramco to Develop Yeast-Based Biosynthesis Platform for Production and Distribution of CBD - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - June 5, 2019) - Willow Biosciences (CSE: WLLW) and Noramco, Inc. have entered into an exclusive Joint Development Agreement to collaboratively develop a yeast-based biosynthesis platform for the production and distribution of CBD. As a technology platform, biosynthesis can provide a low-cost, ultra-pure and scalable manufacturing solution for pharmaceutical, food, beverage and personal care consumers of CBD.For more information, please view the InvestmentPitch Media "video" which provides additional ...

  • CNW Group21 days ago

    Willow Biosciences and Noramco Announce Joint Development of Biosynthesis Platform for Cannabidiol

    CALGARY , June 4, 2019 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (WLLW.CN), a leading developer of biosynthetic production systems for plant-derived active pharmaceutical ingredients ("APIs") and intermediates, and Noramco, Inc. ("Noramco"), a leading manufacturer of cannabinoids, are pleased to announce that they have entered into an exclusive Joint Development Agreement ("JDA") to collaboratively develop a yeast-based biosynthesis platform for the production and distribution of cannabidiol ("CBD"). As a technology platform, biosynthesis can provide a low-cost, ultra-pure and scalable manufacturing solution for pharmaceutical, food, beverage and personal care consumers of CBD.

  • Newsfile26 days ago

    Willow Biosciences: The Science of Industrial Scale Pharmaceutical Cannabinoid Production -- CFN Media

    Seattle, Washington--(Newsfile Corp. - May 30, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering Willow Biosciences Inc. (CSE: WLLW) and its unique take on cannabis production.With the very recent loosening of restrictions on cannabis research across the world, the pharmaceutical industry is playing catchup following decades prohibition. More than 100 cannabinoids, the active ingredients in ...

  • CNW Group29 days ago

    Willow Biosciences and Tuatara Capital Announce Exercise of Warrants

    CALGARY , May 27, 2019 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (WLLW.CN) and Tuatara Capital Fund II, L.P. ("Tuatara") are pleased to announce that Tuatara has acquired 9,219,390 common shares ("Common Shares") of the Company pursuant to the exercise of Common Share purchase warrants ("Warrants") for proceeds to the Company of $8,066,966.67 (the "Warrant Exercise"). Trevor Peters , President and Chief Executive Officer of Willow, stated "This additional capital from our sector-focused private equity partner, Tuatara, puts us on even stronger financial footing and will accelerate our ability to secure strategic relationships with potential manufacturing and distribution partners.

  • CNW Grouplast month

    IIROC Trade Resumption - WLLW

    IIROC Trade Resumption - WLLW

  • CNW Grouplast month

    IIROC Trading Halt - WLLW

    IIROC Trading Halt - WLLW

  • CNW Grouplast month

    Willow Biosciences Inc. Announces Share Consolidation

    CALGARY , May 14, 2019 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (WLLW.CN) announces that it will be consolidating all of the issued and outstanding common shares of the Company ("Common Shares") on the basis of one (1) post‐consolidation Common Share for each twenty-five (25) pre‐consolidation Common Shares (the "Consolidation"). The Corporation's board of directors set May 17, 2019 as the effective date of the Consolidation.

  • CNW Group2 months ago

    Willow Biosciences Inc. Announces Appointment of Vice President, Corporate Development, Stock Option Grant and Investor Presentation

    CALGARY , May 2, 2019 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (WLLW.CN) is pleased to announce that Troy Talkkari has joined the Company as Vice President, Corporate Development, effective May 1, 2019 . Mr. Talkkari has over 12 years of experience in the finance industry, most recently as a Director of Institutional Equity Sales at GMP FirstEnergy. In his tenure in the Investment Banking group, Mr. Talkkari was involved in 66 M &A transactions for aggregate transaction value of over $22 billion .